Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.86
−$0.10 · -5.10%
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Latest quote
$1.86
−$0.10 · -5.10%
After-hours
$2.01
+$0.15 · +8.06%
Oct 8, 4:55 PM ET
Regular session · ET · Market data may be delayed.
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Day range
Current $1.86
52-week range
Current $1.86
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
38
Expensive
Sentiment
58
Mixed
Risk
82
Extreme Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Day range
Current $1.86
52-week range
Current $1.86
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 14.83K USD | 34.89K USD | 17.07K USD | 950 USD | 901 USD |
| Gross profit | 14.83K USD | 34.89K USD | 17.07K USD | 950 USD | 901 USD |
| Research and development | 641.21K USD | 227.97K USD | 145.18K USD | 40.45K USD | 31.47K USD |
| Selling, general, and administrative | 5.79M USD | 8.15M USD | 7.1M USD | 4.49M USD | 573.88K USD |
| Operating expenses | 6.5M USD | 8.4M USD | 7.26M USD | 4.55M USD | 621.35K USD |
| Interest income | 712 USD | 1.06K USD | 1.07K USD | — | — |
| Interest expense | 14.8K USD | 18.64K USD | 6.74M USD | — | — |
| Depreciation and amortization | 398.13K USD | 276.35K USD | 111.62K USD | 16K USD | 16K USD |
| Operating income | −6.48M USD | −8.37M USD | −7.24M USD | −4.55M USD | −620.45K USD |
| Net income | −6.5M USD | −8.38M USD | −8.38M USD | −4.66M USD | −620.45K USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 13, 2025 | 1:30 | — | — |
Effective May 13, 2025
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
